GlassScriptPhysician profile
Ronan Allencherril
NPI 1306475165
$6,107.76
in general payments reported to CMS, 2019-2025
18 companies · $3,326 in 2025
The $3,326 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $152 · 2024: $2,630 · 2025: $3,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,107.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,691.57 | 2024-2025 | |
| Genzyme Corporation | $924.81 | 2023-2025 | |
| Janssen Biotech, INC. | $565.25 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $424.94 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $382.96 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $377.65 | 2024-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $364.32 | 2024-2025 | Rezdiffra |
| Ardelyx, INC. | $287.01 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $233.17 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.55 | 2024-2025 | Xifaxan, Trulance |
| Celltrion USA INC. | $207.83 | 2024-2025 | Zymfentra, Vegzelma |
| Aimmune Therapeutics, INC. | $166.03 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $36.62 | 2024-2025 | Iqirvo |
| Dynavax Technologies Corporation | $26.03 | 2025 | Heplisav-B |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.27 | 2025 | |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Merck Sharp & Dohme LLC | $18.87 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronan Allencherril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.